MX363351B - Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. - Google Patents

Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.

Info

Publication number
MX363351B
MX363351B MX2014004448A MX2014004448A MX363351B MX 363351 B MX363351 B MX 363351B MX 2014004448 A MX2014004448 A MX 2014004448A MX 2014004448 A MX2014004448 A MX 2014004448A MX 363351 B MX363351 B MX 363351B
Authority
MX
Mexico
Prior art keywords
methods
cancer
treating vascular
leak syndrome
vascular leak
Prior art date
Application number
MX2014004448A
Other languages
English (en)
Spanish (es)
Other versions
MX2014004448A (es
Inventor
Shalwitz Robert
Peters Kevin
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Publication of MX2014004448A publication Critical patent/MX2014004448A/es
Publication of MX363351B publication Critical patent/MX363351B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014004448A 2011-10-13 2012-10-15 Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. MX363351B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546697P 2011-10-13 2011-10-13
US201161546748P 2011-10-13 2011-10-13
PCT/US2012/060273 WO2013056240A1 (en) 2011-10-13 2012-10-15 Methods for treating vascular leak syndrome and cancer

Publications (2)

Publication Number Publication Date
MX2014004448A MX2014004448A (es) 2014-11-10
MX363351B true MX363351B (es) 2019-03-20

Family

ID=48082581

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014004448A MX363351B (es) 2011-10-13 2012-10-15 Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
MX2019002983A MX2019002983A (es) 2011-10-13 2014-04-11 Un agente de union a hptp?-ecd para usarse en el tratamiento de sindrome de fuga vascular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019002983A MX2019002983A (es) 2011-10-13 2014-04-11 Un agente de union a hptp?-ecd para usarse en el tratamiento de sindrome de fuga vascular.

Country Status (10)

Country Link
US (4) US20130095065A1 (OSRAM)
EP (2) EP3505182A1 (OSRAM)
JP (5) JP2014530244A (OSRAM)
CN (1) CN104039351A (OSRAM)
AU (1) AU2012323856B2 (OSRAM)
BR (1) BR112014008819A8 (OSRAM)
CA (1) CA2850830A1 (OSRAM)
HK (1) HK1201178A1 (OSRAM)
MX (2) MX363351B (OSRAM)
WO (1) WO2013056240A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US9096555B2 (en) * 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
PH12012500788A1 (en) 2009-11-06 2016-07-27 Aerpio Therapeutics Inc Compositions and methods for treating colitis
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9440963B2 (en) * 2013-03-15 2016-09-13 Aerpio Therapeutics, Inc. Compositions, formulations and methods for treating ocular diseases
US9902767B2 (en) 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
US9388135B2 (en) 2014-02-19 2016-07-12 Aerpio Therapeutics, Inc. Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
WO2016196774A1 (en) 2015-06-03 2016-12-08 Aelan Cell Technologies, Inc. Methods and devices for the production and delivery of beneficial factors from stem cells
EP3977994B1 (en) 2015-09-23 2024-04-24 EyePoint Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
SG11201900464TA (en) 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3580568A1 (en) 2017-02-09 2019-12-18 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting immunotherapy intervention
US12006354B2 (en) 2017-05-24 2024-06-11 Novartis Ag Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
CN113874002A (zh) * 2019-05-02 2021-12-31 生物切萨皮克有限责任公司 治疗患有中枢神经系统挫伤的受试者的方法
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4673641A (en) 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
ATE222291T1 (de) 1992-03-13 2002-08-15 Organon Teknika Bv Epstein-barr-virus verwandte peptide und nukleinsäuresegmenten
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5688781A (en) 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
JP4122056B2 (ja) 1995-04-06 2008-07-23 リジエネロン ファーマシューティカルズ，インコーポレイテッド Ｔｉｅ−２リガンド、その作製方法および使用方法
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
WO1998018914A1 (en) 1996-10-31 1998-05-07 Duke University Soluble tie2 receptor
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
SI1325932T1 (OSRAM) 1997-04-07 2005-08-31 Genentech Inc
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
EP1165115B1 (en) 1999-03-26 2003-05-28 Regeneron Pharmaceuticals, Inc. Modulation of vascular permeability by mean of tie2 receptor activators
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
AU5062500A (en) 1999-04-26 2000-11-10 Amersham Pharmacia Biotech Ab Primers for identifying typing or classifying nucleic acids
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
AU5147700A (en) 1999-05-19 2000-12-05 Amgen, Inc. Crystal of a lymphocyte kinase-ligand complex and methods of use
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
KR20080068151A (ko) 2000-06-23 2008-07-22 바이엘 쉐링 파마 악티엔게젤샤프트 ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
US6316109B1 (en) 2000-09-21 2001-11-13 Ppg Industries Ohio, Inc. Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers
CZ2003788A3 (cs) 2000-09-27 2003-08-13 The Procter & Gamble Company Ligandy melanokortinového receptoru
US6455026B1 (en) 2001-03-23 2002-09-24 Agy Therapeutics, Inc. Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
EP1437143A4 (en) 2001-09-28 2007-05-09 Santen Pharmaceutical Co Ltd INJECTIONS FOR EYE TISSUE WITH POLYETHYLENE GLYCOL-BOUNDED MEDICINAL PRODUCT
US20050260132A1 (en) 2001-10-17 2005-11-24 Daniel Chin Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
AU2002335085A1 (en) 2001-10-25 2003-05-06 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
EP1450852B1 (en) 2001-12-04 2007-01-17 DeveloGen Aktiengesellschaft Ptp10d nucleic acids and peptides involved in the regulation of energy homeostasis
US20030158083A1 (en) 2002-02-08 2003-08-21 The Procter & Gamble Company Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase
US20030215899A1 (en) 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
WO2003084565A2 (en) 2002-04-08 2003-10-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Ve-ptp as regulator of ve-cadherin mediated processes or disorders
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
AU2003243190A1 (en) 2002-05-03 2003-11-17 Regeneron Pharmaceuticals, Inc. Methods of inducing formation of functional and organized lymphatic vessels
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
US20040167183A1 (en) 2003-02-20 2004-08-26 The Procter & Gamble Company Phenethylamino sulfamic acids
JPWO2004106542A1 (ja) 2003-05-29 2006-07-20 三共株式会社 インスリン抵抗性改善剤及びそのスクリーニング方法
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US20050158320A1 (en) 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
LT2653465T (lt) 2004-03-15 2016-09-12 Janssen Pharmaceutica Nv Opioidinio receptoriaus moduliatoriai
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
DK2457578T3 (en) 2004-09-28 2015-12-07 Aprogen Inc A chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in the treatment of erectile dysfunction of the penis
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
WO2006091209A2 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070154482A1 (en) * 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
US20070134234A1 (en) 2005-09-29 2007-06-14 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP3168234A1 (en) 2005-12-15 2017-05-17 Medimmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
CA2622312A1 (en) 2006-01-30 2007-08-02 (Osi) Eyetech, Inc. Combination therapy for the treatment of neovascular disorders
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8957022B2 (en) 2006-10-27 2015-02-17 Sunnybrook Health Sciences Centre Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2008127727A1 (en) 2007-04-13 2008-10-23 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2009003110A2 (en) 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
US20090002289A1 (en) * 2007-06-28 2009-01-01 Boundary Net, Incorporated Composite display
BRPI0813966A8 (pt) 2007-06-29 2016-02-10 Schering Corp Usos de mdl-1
CA2702637A1 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
DK2385763T3 (en) 2009-01-12 2018-07-16 Aerpio Therapeutics Inc METHODS OF TREATING VASCULAR LEAK SYNDROME
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
WO2010097800A1 (en) 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
CA2753690A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
EP2403342A4 (en) 2009-03-03 2013-06-05 Alcon Res Ltd PHARMACEUTICAL COMPOSITION FOR IL-ADMINISTRATION OF TYROSINE KINASE RECEPTOR INHIBITING COMPOUNDS (RTKI)
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
PH12012500788A1 (en) 2009-11-06 2016-07-27 Aerpio Therapeutics Inc Compositions and methods for treating colitis
BR112012012887A2 (pt) 2009-12-02 2017-05-02 Imaginab Inc minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito.
PL2524693T3 (pl) * 2010-01-14 2014-11-28 Sanwa Kagaku Kenkyusho Co Farmaceutyk do zapobiegania lub leczenia chorób, którym towarzyszy angiogeneza tkanki oka i/lub zwiększona przepuszczalność naczyń krwionośnych oka
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
MX2012014428A (es) 2010-07-12 2013-03-05 Threshold Pharmaceuticals Inc Administracion de profarmacos activados por hipoxia y de agentes antiangiogenicos para el tratamiento de cancer.
CA2818215C (en) 2010-10-07 2015-07-21 Aerpio Therapeutics Inc. Compositions and methods for treating ocular edema, neovascularization and related diseases
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
EP2857032A3 (en) 2010-12-02 2015-07-15 Maruzen Pharmaceuticals Co., Ltd. Tie2 activator, vascular endothelial growth factor (vegf) inhibitor, anti-angiogenic agent, agent for maturing blood vessels, agent for normalizing blood vessels, agent for stabilizing blood vessels, and pharmaceutical composition
EP3222285A1 (en) 2011-01-13 2017-09-27 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CN103402582A (zh) 2011-02-11 2013-11-20 普西维达公司 使用抗水肿疗法治疗黄斑水肿的方法
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
MX2014005358A (es) 2011-11-03 2014-09-12 Tolera Therapeutics Inc Anticuerpo y metodos para la inhibicion selectiva de respuestas mediadas por celulas t.
US20130190324A1 (en) 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
AU2013245630A1 (en) 2012-04-13 2014-10-30 The Johns Hopkins University Treatment of ischemic retinopathies
HUE046134T2 (hu) 2012-05-07 2020-02-28 Allergan Inc Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
LT2880167T (lt) 2012-07-31 2018-10-25 The Board Of Regents Of The University Of Texas System Kasos beta-ląstelių in vivo indukcijos būdai ir kompozicijos
JP2015528454A (ja) 2012-08-28 2015-09-28 ノバルティス アーゲー 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用
CN104755103A (zh) 2012-10-11 2015-07-01 阿森迪斯药物眼科部股份有限公司 用于治疗眼病症的中和vegf的前药
BR112015010566A2 (pt) 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
WO2014079709A1 (en) 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9440963B2 (en) 2013-03-15 2016-09-13 Aerpio Therapeutics, Inc. Compositions, formulations and methods for treating ocular diseases
US10314882B2 (en) 2013-04-11 2019-06-11 Sunnybrook Research Institute Methods, uses and compositions of Tie2 agonists
US20160130321A1 (en) 2013-06-20 2016-05-12 Gabriela Burian Use of a vegf antagonist in treating macular edema
EP3010525A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating choroidal neovascularisation
WO2015002893A1 (en) 2013-07-02 2015-01-08 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
RU2676303C2 (ru) 2013-07-11 2018-12-27 Новартис Аг Использование антагониста vegf для лечения ретролентальной фиброплазии
EP3019526A1 (en) 2013-07-11 2016-05-18 Novartis AG Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
US9902767B2 (en) 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
JP6419794B2 (ja) 2013-10-01 2018-11-07 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 主要な心臓有害事象に罹患する危険性を予測する方法
CN105636986B (zh) 2013-10-18 2020-05-12 瑞泽恩制药公司 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
ES2727532T3 (es) 2013-11-01 2019-10-16 Regeneron Pharma Intervenciones basadas en angiopoyetina para el tratamiento de la malaria cerebral
PL3065761T3 (pl) 2013-11-05 2020-05-18 Allergan, Inc. Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf
AU2015204674B2 (en) 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
US9388135B2 (en) 2014-02-19 2016-07-12 Aerpio Therapeutics, Inc. Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
JP2015199733A (ja) 2014-04-04 2015-11-12 国立大学法人東北大学 眼圧降下剤
US9719135B2 (en) 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
JP2017532953A (ja) 2014-09-16 2017-11-09 オバサイエンス・インコーポレイテッド 抗ｖａｓａ抗体、ならびにその産生法および使用法
US20160082129A1 (en) 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN112826934A (zh) 2014-12-11 2021-05-25 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
WO2016115092A1 (en) 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
WO2016156596A1 (en) 2015-04-02 2016-10-06 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
RU2763916C2 (ru) 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител
EP3977994B1 (en) 2015-09-23 2024-04-24 EyePoint Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
EP3478717B1 (en) 2016-07-04 2022-01-05 F. Hoffmann-La Roche AG Novel antibody format
SG11201900464TA (en) 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
SG10202103032QA (en) 2016-10-04 2021-05-28 Asclepix Therapeutics Inc Compounds and methods for activating tie2 signaling
IT201600120314A1 (it) 2016-11-28 2018-05-28 Nuovo Pignone Tecnologie Srl Turbo-compressore e metodo di funzionamento di un turbo-compressore
US10426817B2 (en) 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
EP3630148A4 (en) 2017-05-26 2021-06-16 The Johns Hopkins University MULTIFUNCTIONAL ANTIBODY LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
CN107602702A (zh) 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 一种同时靶向人p185和血管内皮生长因子的抗体及其应用
CN111465407A (zh) 2017-11-30 2020-07-28 瑞泽恩制药公司 使用vegf拮抗剂治疗生血管性眼病
KR102469248B1 (ko) 2018-02-28 2022-11-22 에이피 바이오사이언시스, 아이엔씨. 표적치료법을 위한 체크포인트 억제력을 갖는 이중작용성 단백질
JP6938796B2 (ja) 2018-03-16 2021-09-22 ノバルティス アーゲー 眼疾患を治療するための方法
US10276202B1 (en) 2018-04-23 2019-04-30 Western Digital Technologies, Inc. Heat-assisted magnetic recording (HAMR) medium with rhodium or rhodium-based alloy heat-sink layer
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
AU2019269628A1 (en) 2018-05-17 2020-12-03 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
US11066476B2 (en) 2018-09-14 2021-07-20 Shanghai tongji hospital Asymmetric bispecific antibody
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF

Also Published As

Publication number Publication date
CA2850830A1 (en) 2013-04-18
US12043664B2 (en) 2024-07-23
AU2012323856A1 (en) 2014-04-17
WO2013056240A1 (en) 2013-04-18
BR112014008819A2 (pt) 2017-06-13
MX2014004448A (es) 2014-11-10
JP2017200947A (ja) 2017-11-09
JP6706367B2 (ja) 2020-06-03
CN104039351A (zh) 2014-09-10
JP2019151673A (ja) 2019-09-12
JP2019151653A (ja) 2019-09-12
EP2766043A4 (en) 2015-06-10
US10150811B2 (en) 2018-12-11
JP2014530244A (ja) 2014-11-17
US20180009890A1 (en) 2018-01-11
BR112014008819A8 (pt) 2017-09-12
EP3505182A1 (en) 2019-07-03
AU2012323856B2 (en) 2017-05-25
JP2017165786A (ja) 2017-09-21
US20210095017A1 (en) 2021-04-01
US20190177409A1 (en) 2019-06-13
NZ623283A (en) 2016-05-27
HK1201178A1 (en) 2015-08-28
US10815300B2 (en) 2020-10-27
EP2766043A1 (en) 2014-08-20
US20130095065A1 (en) 2013-04-18
MX2019002983A (es) 2023-04-12

Similar Documents

Publication Publication Date Title
MX2019002983A (es) Un agente de union a hptp?-ecd para usarse en el tratamiento de sindrome de fuga vascular.
EA201400178A1 (ru) Лечение рака молочной железы
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
EA201490944A1 (ru) Двойной ингибитор met и vegf для лечения рака
CY1123716T1 (el) Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX2014000363A (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA201200998A1 (ru) Способы лечения рака поджелудочной железы
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
MY178390A (en) Inhibitors of iap
IN2014DN08385A (OSRAM)
MX2013013685A (es) Metodo para tratar articulos con dioxido de carbono.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
IN2014DN00254A (OSRAM)
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists
MX2015013021A (es) 5-bromo-indirrubinas.
WO2011153485A3 (en) Use of the sparc microenvironment signature in the treatment of cancer
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
MX2013002111A (es) Metodos y composiciones para el tratamiento de metastasis del cancer.
EA201201647A1 (ru) Способ получения f-18 меченных лигандов бета-амилоида
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
MX350868B (es) Medicamentos y metodos para tratar cancer.
UY34069A (es) Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia
BR112013032188A2 (pt) composição, produto e método para tratar pacientes com hepatite c crônica